| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mouth Neoplasms | 16 | 2024 | 735 | 2.790 |
Why?
|
| Carcinoma, Squamous Cell | 43 | 2024 | 5604 | 2.430 |
Why?
|
| Head and Neck Neoplasms | 35 | 2024 | 4148 | 1.690 |
Why?
|
| Papillomavirus Infections | 13 | 2024 | 999 | 1.160 |
Why?
|
| Tumor Suppressor Protein p53 | 23 | 2024 | 3656 | 1.140 |
Why?
|
| Mutation | 28 | 2023 | 15917 | 0.900 |
Why?
|
| Caspase 8 | 4 | 2020 | 146 | 0.890 |
Why?
|
| Tongue Neoplasms | 4 | 2022 | 253 | 0.760 |
Why?
|
| Papillomaviridae | 10 | 2022 | 636 | 0.580 |
Why?
|
| Mouth | 1 | 2018 | 125 | 0.550 |
Why?
|
| DNA Methylation | 5 | 2018 | 2768 | 0.540 |
Why?
|
| F-Box Proteins | 2 | 2013 | 96 | 0.500 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2015 | 79 | 0.490 |
Why?
|
| DNA Copy Number Variations | 4 | 2015 | 1576 | 0.480 |
Why?
|
| Promoter Regions, Genetic | 4 | 2020 | 3205 | 0.480 |
Why?
|
| Precancerous Conditions | 6 | 2022 | 1061 | 0.480 |
Why?
|
| Genes, bcl-1 | 1 | 2013 | 25 | 0.440 |
Why?
|
| Cell Line, Tumor | 29 | 2024 | 14878 | 0.440 |
Why?
|
| Cell Cycle Proteins | 7 | 2022 | 2112 | 0.440 |
Why?
|
| Angiogenic Proteins | 1 | 2013 | 39 | 0.430 |
Why?
|
| Maxillary Sinus Neoplasms | 3 | 2019 | 114 | 0.420 |
Why?
|
| Nitrophenols | 1 | 2013 | 95 | 0.420 |
Why?
|
| Ubiquitin-Protein Ligases | 3 | 2022 | 866 | 0.390 |
Why?
|
| Biphenyl Compounds | 1 | 2013 | 188 | 0.390 |
Why?
|
| Radiation Tolerance | 5 | 2021 | 639 | 0.390 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2013 | 288 | 0.380 |
Why?
|
| Alphapapillomavirus | 3 | 2022 | 172 | 0.370 |
Why?
|
| Histone Deacetylases | 1 | 2013 | 362 | 0.360 |
Why?
|
| Receptors, Opioid, mu | 2 | 2021 | 96 | 0.360 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2024 | 1704 | 0.350 |
Why?
|
| Receptor, Notch1 | 6 | 2019 | 216 | 0.350 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2017 | 617 | 0.340 |
Why?
|
| Saliva | 2 | 2024 | 232 | 0.330 |
Why?
|
| Clinical Medicine | 1 | 2009 | 26 | 0.320 |
Why?
|
| Humans | 82 | 2024 | 270713 | 0.320 |
Why?
|
| Gene Expression Regulation, Neoplastic | 11 | 2024 | 9048 | 0.310 |
Why?
|
| Research Personnel | 1 | 2009 | 165 | 0.290 |
Why?
|
| Biomarkers, Tumor | 12 | 2024 | 10726 | 0.290 |
Why?
|
| MicroRNAs | 5 | 2024 | 2882 | 0.280 |
Why?
|
| Smoking | 3 | 2020 | 2549 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1544 | 0.270 |
Why?
|
| Biomedical Research | 2 | 2014 | 799 | 0.270 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2024 | 1535 | 0.260 |
Why?
|
| Medical Oncology | 1 | 2014 | 1464 | 0.260 |
Why?
|
| Carcinoma | 5 | 2019 | 2610 | 0.260 |
Why?
|
| Cell Proliferation | 11 | 2021 | 7232 | 0.250 |
Why?
|
| Mouth Mucosa | 2 | 2023 | 223 | 0.250 |
Why?
|
| Genes, p53 | 7 | 2022 | 1140 | 0.240 |
Why?
|
| Checkpoint Kinase 1 | 4 | 2020 | 169 | 0.240 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 7 | 2022 | 508 | 0.230 |
Why?
|
| DNA Damage | 6 | 2022 | 1991 | 0.230 |
Why?
|
| Tumor Microenvironment | 7 | 2024 | 3054 | 0.220 |
Why?
|
| Ultraviolet Rays | 2 | 2024 | 588 | 0.220 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 3 | 2018 | 52 | 0.220 |
Why?
|
| Sulfonamides | 1 | 2013 | 1942 | 0.220 |
Why?
|
| Prognosis | 11 | 2024 | 22528 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2017 | 2618 | 0.200 |
Why?
|
| Male | 33 | 2024 | 128479 | 0.200 |
Why?
|
| Calculi | 1 | 2022 | 20 | 0.200 |
Why?
|
| Oncogene Proteins, Viral | 1 | 2022 | 148 | 0.200 |
Why?
|
| Genomics | 7 | 2024 | 2832 | 0.200 |
Why?
|
| Lymphatic Metastasis | 2 | 2024 | 4969 | 0.190 |
Why?
|
| Apoptosis | 10 | 2022 | 7755 | 0.190 |
Why?
|
| Cisplatin | 4 | 2024 | 2508 | 0.190 |
Why?
|
| Signal Transduction | 13 | 2024 | 12042 | 0.190 |
Why?
|
| Skin Neoplasms | 2 | 2016 | 4899 | 0.190 |
Why?
|
| CREB-Binding Protein | 1 | 2021 | 97 | 0.190 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2021 | 97 | 0.190 |
Why?
|
| Naltrexone | 1 | 2021 | 99 | 0.180 |
Why?
|
| Caspase Inhibitors | 1 | 2020 | 95 | 0.180 |
Why?
|
| Biomimetics | 1 | 2020 | 37 | 0.180 |
Why?
|
| Female | 34 | 2024 | 148885 | 0.180 |
Why?
|
| Homologous Recombination | 1 | 2021 | 188 | 0.180 |
Why?
|
| Gain of Function Mutation | 1 | 2021 | 133 | 0.180 |
Why?
|
| Tympanoplasty | 1 | 2020 | 12 | 0.180 |
Why?
|
| Dipeptides | 1 | 2020 | 96 | 0.180 |
Why?
|
| Adrenergic Neurons | 1 | 2020 | 12 | 0.170 |
Why?
|
| S Phase | 2 | 2017 | 289 | 0.170 |
Why?
|
| Narcotic Antagonists | 1 | 2021 | 155 | 0.170 |
Why?
|
| Mitochondrial Proteins | 2 | 2020 | 377 | 0.170 |
Why?
|
| LIM Domain Proteins | 2 | 2017 | 103 | 0.170 |
Why?
|
| Quinazolines | 2 | 2016 | 956 | 0.170 |
Why?
|
| Disease Progression | 6 | 2020 | 6881 | 0.170 |
Why?
|
| Learning Curve | 1 | 2020 | 79 | 0.170 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 3 | 2017 | 80 | 0.170 |
Why?
|
| Histone Acetyltransferases | 1 | 2021 | 433 | 0.170 |
Why?
|
| Gene Expression | 5 | 2019 | 3606 | 0.160 |
Why?
|
| Oncogenes | 2 | 2020 | 697 | 0.160 |
Why?
|
| Cell Transdifferentiation | 1 | 2020 | 114 | 0.160 |
Why?
|
| NIMA-Related Kinases | 1 | 2018 | 16 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 3 | 2018 | 2363 | 0.160 |
Why?
|
| Tumor Suppressor Proteins | 4 | 2022 | 1901 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 5 | 2023 | 1404 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2014 | 1127 | 0.160 |
Why?
|
| Penile Neoplasms | 1 | 2021 | 183 | 0.160 |
Why?
|
| Mice, Nude | 7 | 2021 | 4332 | 0.160 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2020 | 271 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2024 | 2051 | 0.150 |
Why?
|
| Proteomics | 3 | 2017 | 1425 | 0.150 |
Why?
|
| Sensory Receptor Cells | 1 | 2020 | 157 | 0.150 |
Why?
|
| Transcription Factors, TFII | 1 | 2018 | 23 | 0.150 |
Why?
|
| Caspases | 1 | 2020 | 672 | 0.150 |
Why?
|
| Otolaryngology | 1 | 2020 | 146 | 0.150 |
Why?
|
| Delirium | 1 | 2021 | 208 | 0.150 |
Why?
|
| Indazoles | 1 | 2020 | 310 | 0.150 |
Why?
|
| Antineoplastic Agents | 6 | 2021 | 14638 | 0.150 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2020 | 622 | 0.150 |
Why?
|
| Cellular Reprogramming | 1 | 2020 | 203 | 0.150 |
Why?
|
| Middle Aged | 21 | 2024 | 90533 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2020 | 1276 | 0.140 |
Why?
|
| Mice | 17 | 2021 | 35421 | 0.140 |
Why?
|
| Cytidine Deaminase | 1 | 2017 | 84 | 0.140 |
Why?
|
| Databases, Genetic | 1 | 2020 | 758 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2021 | 3929 | 0.140 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 7787 | 0.140 |
Why?
|
| Animals | 20 | 2021 | 61357 | 0.140 |
Why?
|
| Checkpoint Kinase 2 | 2 | 2017 | 130 | 0.140 |
Why?
|
| Pteridines | 1 | 2017 | 35 | 0.140 |
Why?
|
| Pyrazoles | 4 | 2020 | 1551 | 0.140 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 209 | 0.140 |
Why?
|
| Endoscopy | 1 | 2020 | 495 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 704 | 0.140 |
Why?
|
| Thiophenes | 2 | 2017 | 147 | 0.140 |
Why?
|
| Disease-Free Survival | 3 | 2018 | 10268 | 0.130 |
Why?
|
| Keratosis, Actinic | 1 | 2016 | 39 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 4 | 2021 | 5417 | 0.130 |
Why?
|
| Neoplasm Proteins | 4 | 2018 | 3345 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2017 | 252 | 0.130 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2019 | 294 | 0.130 |
Why?
|
| Adult | 17 | 2024 | 82041 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 341 | 0.130 |
Why?
|
| Genome, Human | 2 | 2015 | 1896 | 0.130 |
Why?
|
| Urea | 2 | 2017 | 301 | 0.130 |
Why?
|
| CpG Islands | 2 | 2015 | 669 | 0.130 |
Why?
|
| Gene Expression Profiling | 5 | 2024 | 5145 | 0.130 |
Why?
|
| Malate Dehydrogenase | 1 | 2015 | 20 | 0.130 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2016 | 116 | 0.130 |
Why?
|
| Mitochondria | 2 | 2020 | 1292 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 5 | 2021 | 2396 | 0.120 |
Why?
|
| Polymorphism, Genetic | 2 | 2018 | 1557 | 0.120 |
Why?
|
| Indoles | 1 | 2020 | 1029 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2020 | 529 | 0.120 |
Why?
|
| Hand Deformities, Congenital | 1 | 2015 | 95 | 0.120 |
Why?
|
| Chromosome Duplication | 1 | 2015 | 154 | 0.120 |
Why?
|
| Aged | 16 | 2024 | 73613 | 0.120 |
Why?
|
| Hydroxamic Acids | 1 | 2017 | 454 | 0.120 |
Why?
|
| Dendritic Cells | 1 | 2021 | 1104 | 0.120 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 1098 | 0.120 |
Why?
|
| Cluster Analysis | 2 | 2014 | 1076 | 0.120 |
Why?
|
| Thymoma | 1 | 2018 | 252 | 0.120 |
Why?
|
| Gene Silencing | 2 | 2014 | 825 | 0.120 |
Why?
|
| Neoplasms, Squamous Cell | 2 | 2011 | 84 | 0.120 |
Why?
|
| DNA Mutational Analysis | 3 | 2016 | 2356 | 0.120 |
Why?
|
| Piperidines | 1 | 2020 | 1099 | 0.120 |
Why?
|
| Phenotype | 4 | 2022 | 6502 | 0.110 |
Why?
|
| Uterine Cervical Neoplasms | 2 | 2022 | 1903 | 0.110 |
Why?
|
| Telomerase | 1 | 2017 | 544 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2014 | 89 | 0.110 |
Why?
|
| Lung Neoplasms | 3 | 2023 | 12039 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2018 | 517 | 0.110 |
Why?
|
| ras Proteins | 2 | 2017 | 804 | 0.110 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 414 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 3 | 2015 | 2560 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 677 | 0.110 |
Why?
|
| Computational Biology | 2 | 2021 | 1295 | 0.100 |
Why?
|
| Thymus Neoplasms | 1 | 2018 | 416 | 0.100 |
Why?
|
| ErbB Receptors | 3 | 2020 | 2376 | 0.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 16741 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2015 | 675 | 0.100 |
Why?
|
| Cohort Studies | 4 | 2018 | 9463 | 0.100 |
Why?
|
| Proteome | 1 | 2016 | 570 | 0.100 |
Why?
|
| Statistics as Topic | 1 | 2013 | 448 | 0.100 |
Why?
|
| Pyrimidinones | 3 | 2020 | 319 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2020 | 1331 | 0.100 |
Why?
|
| Alleles | 1 | 2018 | 2598 | 0.100 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2022 | 64 | 0.100 |
Why?
|
| Enzyme Inhibitors | 2 | 2017 | 1944 | 0.100 |
Why?
|
| Cell Line | 2 | 2018 | 5313 | 0.100 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 1337 | 0.100 |
Why?
|
| Neoplasm Transplantation | 3 | 2020 | 1553 | 0.090 |
Why?
|
| Case-Control Studies | 4 | 2024 | 6233 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 2013 | 228 | 0.090 |
Why?
|
| Pyrimidines | 3 | 2020 | 3671 | 0.090 |
Why?
|
| Mutant Proteins | 1 | 2011 | 233 | 0.090 |
Why?
|
| Neoplasms | 4 | 2024 | 15949 | 0.090 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 31116 | 0.090 |
Why?
|
| Receptors, Notch | 1 | 2013 | 370 | 0.090 |
Why?
|
| Point Mutation | 1 | 2013 | 785 | 0.090 |
Why?
|
| RNA, Messenger | 4 | 2024 | 6344 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2013 | 5777 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2009 | 495 | 0.090 |
Why?
|
| Activins | 1 | 2009 | 93 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2015 | 5099 | 0.080 |
Why?
|
| Colon | 1 | 2013 | 684 | 0.080 |
Why?
|
| DNA-Binding Proteins | 3 | 2018 | 4992 | 0.080 |
Why?
|
| Tumor Burden | 3 | 2021 | 2033 | 0.080 |
Why?
|
| Cell Nucleus | 3 | 2023 | 1715 | 0.080 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 2 | 2021 | 78 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 617 | 0.080 |
Why?
|
| Proteins | 1 | 2017 | 2030 | 0.080 |
Why?
|
| Retinoblastoma Protein | 3 | 2022 | 339 | 0.080 |
Why?
|
| Patient-Specific Modeling | 2 | 2020 | 27 | 0.080 |
Why?
|
| Exome | 1 | 2014 | 1249 | 0.080 |
Why?
|
| Protein Kinases | 1 | 2013 | 889 | 0.080 |
Why?
|
| Glutamine | 1 | 2011 | 325 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2019 | 4965 | 0.080 |
Why?
|
| Neoplasm Staging | 6 | 2021 | 14033 | 0.080 |
Why?
|
| Transcription Factors | 2 | 2020 | 5415 | 0.080 |
Why?
|
| Schools, Medical | 1 | 2009 | 130 | 0.080 |
Why?
|
| Leukoplakia, Oral | 2 | 2023 | 71 | 0.080 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2021 | 1002 | 0.080 |
Why?
|
| Taiwan | 2 | 2017 | 99 | 0.070 |
Why?
|
| Immunotherapy | 1 | 2021 | 3561 | 0.070 |
Why?
|
| Sequence Analysis, RNA | 2 | 2024 | 674 | 0.070 |
Why?
|
| Lymph Nodes | 1 | 2018 | 3081 | 0.070 |
Why?
|
| Neoplasm Invasiveness | 3 | 2021 | 4054 | 0.070 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2020 | 1837 | 0.070 |
Why?
|
| Physicians | 1 | 2014 | 854 | 0.070 |
Why?
|
| Phosphorylation | 4 | 2018 | 4907 | 0.060 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 679 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2021 | 2419 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 3 | 2021 | 7052 | 0.060 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 2658 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2011 | 1126 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2020 | 39959 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2013 | 1435 | 0.060 |
Why?
|
| DNA, Viral | 2 | 2022 | 748 | 0.060 |
Why?
|
| HIV Infections | 1 | 2017 | 2155 | 0.060 |
Why?
|
| Fellowships and Scholarships | 1 | 2009 | 417 | 0.060 |
Why?
|
| Glucose | 1 | 2011 | 1214 | 0.060 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 10404 | 0.060 |
Why?
|
| Down-Regulation | 3 | 2015 | 2087 | 0.060 |
Why?
|
| Age Factors | 1 | 2014 | 5441 | 0.060 |
Why?
|
| Sequence Deletion | 2 | 2017 | 908 | 0.060 |
Why?
|
| RNA, Small Untranslated | 1 | 2024 | 31 | 0.060 |
Why?
|
| Ethiopia | 1 | 2024 | 29 | 0.060 |
Why?
|
| Gene Knockdown Techniques | 2 | 2019 | 1072 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 231 | 0.060 |
Why?
|
| Piperazines | 1 | 2013 | 2145 | 0.060 |
Why?
|
| Nucleotidyltransferases | 1 | 2024 | 96 | 0.060 |
Why?
|
| DNA Replication | 2 | 2017 | 768 | 0.060 |
Why?
|
| Gene Dosage | 3 | 2016 | 822 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 344 | 0.050 |
Why?
|
| Genetic Association Studies | 2 | 2020 | 1098 | 0.050 |
Why?
|
| Genotype | 3 | 2022 | 4248 | 0.050 |
Why?
|
| Curriculum | 1 | 2009 | 911 | 0.050 |
Why?
|
| Breast | 2 | 2006 | 1370 | 0.050 |
Why?
|
| ATPases Associated with Diverse Cellular Activities | 1 | 2022 | 86 | 0.050 |
Why?
|
| Fusobacterium | 1 | 2022 | 12 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2024 | 228 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2017 | 6257 | 0.050 |
Why?
|
| Aurora Kinases | 1 | 2022 | 193 | 0.050 |
Why?
|
| Interferons | 1 | 2024 | 297 | 0.050 |
Why?
|
| Ubiquitin-Specific Peptidase 7 | 1 | 2022 | 40 | 0.050 |
Why?
|
| Genetic Fitness | 1 | 2022 | 41 | 0.050 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2005 | 690 | 0.050 |
Why?
|
| Conjunctiva | 1 | 2024 | 224 | 0.050 |
Why?
|
| Cellular Senescence | 2 | 2015 | 389 | 0.050 |
Why?
|
| Nuclear Proteins | 3 | 2017 | 3435 | 0.050 |
Why?
|
| Blotting, Western | 3 | 2014 | 3568 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2020 | 9281 | 0.050 |
Why?
|
| Radiobiology | 1 | 2021 | 56 | 0.050 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2021 | 66 | 0.050 |
Why?
|
| Epithelial Cells | 2 | 2006 | 1874 | 0.050 |
Why?
|
| Optical Imaging | 1 | 2022 | 158 | 0.050 |
Why?
|
| Transcriptome | 2 | 2024 | 1959 | 0.050 |
Why?
|
| Selection, Genetic | 1 | 2022 | 196 | 0.050 |
Why?
|
| Carcinogenicity Tests | 1 | 2001 | 69 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 81 | 0.050 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 62 | 0.050 |
Why?
|
| Cell Communication | 1 | 2023 | 509 | 0.050 |
Why?
|
| Prevalence | 2 | 2021 | 3395 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2022 | 571 | 0.050 |
Why?
|
| Deoxyglucose | 2 | 2011 | 119 | 0.050 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2021 | 104 | 0.050 |
Why?
|
| Biological Evolution | 1 | 2022 | 289 | 0.040 |
Why?
|
| TNF Receptor-Associated Factor 3 | 1 | 2020 | 22 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 85 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2015 | 15275 | 0.040 |
Why?
|
| Adrenergic Antagonists | 1 | 2020 | 20 | 0.040 |
Why?
|
| Ubiquitin | 1 | 2022 | 311 | 0.040 |
Why?
|
| Acetylation | 1 | 2021 | 516 | 0.040 |
Why?
|
| Tobacco Use | 1 | 2020 | 63 | 0.040 |
Why?
|
| Hearing Disorders | 1 | 2020 | 34 | 0.040 |
Why?
|
| Transfection | 2 | 2017 | 3109 | 0.040 |
Why?
|
| Protein Domains | 1 | 2021 | 317 | 0.040 |
Why?
|
| Adenosine Triphosphatases | 1 | 2022 | 428 | 0.040 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2022 | 509 | 0.040 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2005 | 690 | 0.040 |
Why?
|
| Receptors, Adrenergic | 1 | 2020 | 53 | 0.040 |
Why?
|
| Mutagens | 1 | 2001 | 189 | 0.040 |
Why?
|
| Neurites | 1 | 2020 | 70 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 316 | 0.040 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 7317 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 5056 | 0.040 |
Why?
|
| Bronchi | 1 | 2021 | 325 | 0.040 |
Why?
|
| Carcinogens | 1 | 2001 | 390 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2020 | 119 | 0.040 |
Why?
|
| Feedback, Physiological | 1 | 2020 | 191 | 0.040 |
Why?
|
| Medical Audit | 1 | 2020 | 194 | 0.040 |
Why?
|
| Metformin | 2 | 2015 | 397 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2017 | 1801 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2018 | 2134 | 0.040 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2020 | 506 | 0.040 |
Why?
|
| PubMed | 1 | 2018 | 32 | 0.040 |
Why?
|
| Carcinogenesis | 2 | 2016 | 1034 | 0.040 |
Why?
|
| Breast Neoplasms | 3 | 2009 | 16244 | 0.040 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 9053 | 0.040 |
Why?
|
| Reactive Oxygen Species | 2 | 2015 | 1004 | 0.040 |
Why?
|
| Age of Onset | 1 | 2020 | 853 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 528 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2020 | 33847 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 546 | 0.040 |
Why?
|
| Loss of Function Mutation | 1 | 2019 | 164 | 0.040 |
Why?
|
| Receptor, Notch2 | 1 | 2017 | 22 | 0.040 |
Why?
|
| HCT116 Cells | 1 | 2018 | 354 | 0.040 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2020 | 368 | 0.040 |
Why?
|
| Models, Genetic | 1 | 2022 | 1161 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2018 | 112 | 0.040 |
Why?
|
| HLA-A Antigens | 1 | 2017 | 105 | 0.040 |
Why?
|
| Neoplasms, Experimental | 1 | 2001 | 784 | 0.040 |
Why?
|
| Cetuximab | 1 | 2019 | 474 | 0.040 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2017 | 118 | 0.040 |
Why?
|
| NF-kappa B | 1 | 2024 | 1555 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 57 | 0.030 |
Why?
|
| Pharmacogenetics | 1 | 2018 | 267 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2018 | 492 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2018 | 731 | 0.030 |
Why?
|
| Gene Editing | 1 | 2019 | 229 | 0.030 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2017 | 224 | 0.030 |
Why?
|
| RNA, Neoplasm | 1 | 2019 | 805 | 0.030 |
Why?
|
| Young Adult | 3 | 2020 | 22243 | 0.030 |
Why?
|
| Transcription, Genetic | 2 | 2020 | 3328 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2021 | 1828 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2021 | 732 | 0.030 |
Why?
|
| Smad4 Protein | 1 | 2017 | 201 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2017 | 1044 | 0.030 |
Why?
|
| Alu Elements | 1 | 2015 | 89 | 0.030 |
Why?
|
| Cell Division | 1 | 2020 | 2657 | 0.030 |
Why?
|
| Carboplatin | 1 | 2019 | 889 | 0.030 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2017 | 256 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2019 | 362 | 0.030 |
Why?
|
| DNA | 1 | 2024 | 3041 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2017 | 591 | 0.030 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 521 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 1092 | 0.030 |
Why?
|
| 14-3-3 Proteins | 1 | 2015 | 141 | 0.030 |
Why?
|
| Adenocarcinoma | 1 | 2013 | 7920 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 930 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 982 | 0.030 |
Why?
|
| Radiation, Ionizing | 1 | 2015 | 190 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 2478 | 0.030 |
Why?
|
| Fluorouracil | 1 | 2019 | 1990 | 0.030 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2017 | 463 | 0.030 |
Why?
|
| Cadherins | 1 | 2017 | 659 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2021 | 5692 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2018 | 1458 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2014 | 47 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2017 | 1355 | 0.030 |
Why?
|
| Paired Box Transcription Factors | 1 | 2014 | 128 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2015 | 538 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2015 | 866 | 0.030 |
Why?
|
| Carrier Proteins | 1 | 2022 | 2085 | 0.030 |
Why?
|
| Cell Movement | 1 | 2021 | 2468 | 0.030 |
Why?
|
| Genetic Loci | 1 | 2015 | 501 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2021 | 1716 | 0.030 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 336 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2017 | 1195 | 0.030 |
Why?
|
| Benzamides | 1 | 2018 | 1879 | 0.030 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2014 | 398 | 0.030 |
Why?
|
| RNA Interference | 1 | 2017 | 1381 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 17861 | 0.020 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2015 | 626 | 0.020 |
Why?
|
| DNA Repair | 1 | 2020 | 1906 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1101 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2017 | 1032 | 0.020 |
Why?
|
| Cesium Radioisotopes | 1 | 2011 | 38 | 0.020 |
Why?
|
| Pedigree | 1 | 2015 | 2040 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2019 | 2114 | 0.020 |
Why?
|
| Genetic Heterogeneity | 1 | 2013 | 338 | 0.020 |
Why?
|
| Bile Acids and Salts | 1 | 2013 | 270 | 0.020 |
Why?
|
| INDEL Mutation | 1 | 2011 | 114 | 0.020 |
Why?
|
| Skin | 1 | 2016 | 1281 | 0.020 |
Why?
|
| Mitosis | 1 | 2013 | 681 | 0.020 |
Why?
|
| Codon, Nonsense | 1 | 2011 | 159 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2011 | 244 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2017 | 5759 | 0.020 |
Why?
|
| Lung | 1 | 2021 | 3284 | 0.020 |
Why?
|
| Telomeric Repeat Binding Protein 2 | 1 | 2009 | 29 | 0.020 |
Why?
|
| Mucous Membrane | 1 | 2011 | 258 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 418 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 4838 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2015 | 1958 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2011 | 352 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2011 | 627 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 1051 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 7648 | 0.020 |
Why?
|
| Lactic Acid | 1 | 2011 | 312 | 0.020 |
Why?
|
| Binding Sites | 1 | 2013 | 2249 | 0.020 |
Why?
|
| Base Sequence | 1 | 2015 | 5405 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2011 | 414 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2011 | 573 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 580 | 0.020 |
Why?
|
| Glycolysis | 1 | 2011 | 529 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 6639 | 0.020 |
Why?
|
| Protein Array Analysis | 1 | 2011 | 503 | 0.020 |
Why?
|
| Mass Spectrometry | 1 | 2011 | 721 | 0.020 |
Why?
|
| Adolescent | 2 | 2019 | 32689 | 0.020 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2009 | 437 | 0.020 |
Why?
|
| Exons | 1 | 2011 | 1388 | 0.020 |
Why?
|
| Cell Survival | 1 | 2013 | 3057 | 0.020 |
Why?
|
| Metabolomics | 1 | 2011 | 503 | 0.020 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2011 | 444 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 5332 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2011 | 601 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 1503 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5048 | 0.020 |
Why?
|
| United States | 1 | 2024 | 15828 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2006 | 132 | 0.020 |
Why?
|
| Survival Rate | 1 | 2020 | 12530 | 0.020 |
Why?
|
| Telomere | 1 | 2009 | 546 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 489 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2011 | 1196 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2021 | 13419 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2014 | 5157 | 0.020 |
Why?
|
| Prostaglandins | 1 | 2005 | 84 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 6766 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 4644 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2009 | 3582 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 12978 | 0.010 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 1235 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 702 | 0.010 |
Why?
|
| Animal Testing Alternatives | 1 | 2001 | 4 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 6193 | 0.010 |
Why?
|
| Thyroid Neoplasms | 1 | 2011 | 1908 | 0.010 |
Why?
|
| Infant | 1 | 2015 | 13994 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 623 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 5657 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2005 | 2922 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2001 | 4202 | 0.010 |
Why?
|